INTER-AF
INTER-AF is a worldwide collaboration for the observational study of Atrial Fibrillation (AFib). It provides a global platform for investigators and countries to study AFib populations, treatments, and outcomes.
INTER-AF is a collaborative consortium of AFib registries seeking to characterize worldwide AFib care and establish a global platform for ongoing efforts to optimize AFib treatment.
|
INTER-AF is organized as a distributed research network, which allows for data collection and local analyses to be conducted within each participating partner's infrastructure. These data are then aggregated and analyzed across partner registries.
INTER-AF will provide insight into international AFib care across a global spectrum of countries, with the potential to adapt to temporal changes in treatment strategies. Since INTER-AF will collect data longitudinally, it will be able to capture all types of oral anticoagulationstrategies (warfarin versus DOACs), and rhythm-control strategies (antiarrhythmic drug medications and ablation). This will allow for a broad spectrum of treatment analyses.
To date, most other global registries focus only on a specific treatment protocol. Ongoing shared data collection and analyses that is not limited by a specific end date allows for evolution of the global registry standard. INTER-AF will provide longitudinal information on changing practice patterns by using a distributive analytic method for data collection and analyses and expanding information collected to several different aspects of AFib care.
The founding partners of INTER-AF include representatives from the United States, Europe, China, Brazil, South Korea, Taiwan, Singapore, Japan, and the Balkan countries. Each of the partners oversees country- or region-specific AFib registries.
|
*INTER-AF is supported by an unrestricted award from Bristol-Myers Squibb and Pfizer, Inc. to the American College of Cardiology Foundation. The funders have no role in project governance, management, or research activities.